Trial Profile
Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers. A Monocentric, Open Label, Cross-over Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Diabetic neuropathies; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Jun 2014 New trial record